Therapeutic Area | MeSH |
---|---|
eye diseases | D005128 |
signs and symptoms pathological conditions | D013568 |
Brand Name | Status | Last Update |
---|---|---|
flarex | New Drug Application | 2025-03-31 |
fluorometholone | NDA authorized generic | 2020-09-24 |
fluorometholone ophthalmic suspension | ANDA | 2024-01-09 |
fml | New Drug Application | 2023-12-15 |
fml forte | New Drug Application | 2025-02-13 |
fml-s | 2007-02-20 |
Expiration | Code | ||
---|---|---|---|
FLUOROMETHOLONE, FLUOROMETHOLONE, AMNEAL | |||
2024-07-07 | CGT |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Lacrimal apparatus diseases | D007766 | — | H04 | — | 1 | — | — | — | 1 |
Drug common name | Fluorometholone |
INN | fluorometholone |
Description | Fluorometholone is a member of the class of glucocorticoids that is Delta(1)-progesterone substituted at positions 11beta and 17 by hydroxy groups, at position 6alpha by a methyl group and at position 9 by a fluoro group. Used for the treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe. It has a role as an anti-inflammatory drug. It is a fluorinated steroid, an 11beta-hydroxy steroid, a 20-oxo steroid, a 3-oxo-Delta(1),Delta(4)-steroid, a glucocorticoid, a 17alpha-hydroxy steroid and a tertiary alpha-hydroxy ketone. It is functionally related to a Delta(1)-progesterone. |
Classification | Small molecule |
Drug class | steroids (not prednisolone derivatives) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C |
PDB | — |
CAS-ID | 426-13-1 |
RxCUI | — |
ChEMBL ID | CHEMBL1200600 |
ChEBI ID | 31625 |
PubChem CID | 9878 |
DrugBank | DB00324 |
UNII ID | SV0CSG527L (ChemIDplus, GSRS) |